FAM78B: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: FAM78B

NCBI ID: G149297

FAM78B

FAM78B: A Potential Drug Target and Biomarker for Ovarian Cancer

Introduction

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 1,600 women in the United States alone every year. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 40% . Therefore, there is a significant need for new treatments and biomarkers to improve outcomes for ovarian cancer patients.

FAM78B: A Potential Drug Target and Biomarker

FAM78B (fostin-like acute myeloid tubulin-78) is a protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It has been identified as a potential drug target for ovarian cancer due to its unique structure and expression pattern.

The FAM78B protein is a member of the acute myeloid tubulin family, which is characterized by the presence of a conserved amino acid sequence that is similar to that of the protein histamine receptor. This family of proteins has been implicated in the regulation of cell signaling pathways, including TGF-β signaling.

FAM78B has been shown to play a role in the regulation of cell proliferation and survival. It has been shown to promote the growth and survival of ovarian cancer cells in cell culture and animal models. Additionally, FAM78B has been shown to interact with the protein PDGF -BB, which is a potent regulator of cell proliferation and survival.

FAM78B as a Biomarker

FAM78B has also been shown to be a potential biomarker for ovarian cancer. The expression of FAM78B has been shown to be associated with the development and progression of ovarian cancer in both humans and animals.

FAM78B has been shown to be overexpressed in ovarian cancer tissue and serum, which suggests that it may be a useful biomarker for the disease. Additionally, the levels of FAM78B have been shown to be correlated with the expression of other ovarian cancer-related genes, such as the oncogenees PIK3CA and CDKN2A.

FAM78B as a Drug Target

The potential drug target for FAM78B is the regulation of cell signaling pathways, particularly the TGF-β signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a target for a variety of anti-cancer drugs , including inhibitors of TGF-β signaling.

FAM78B has been shown to interact with the protein PDGF-BB, which is a potent regulator of TGF-β signaling. This suggests that FAM78B may be a useful target for inhibitors of TGF-β signaling, which could be effective in the treatment of ovarian cancer.

Conclusion

FAM78B is a protein that has been identified as a potential drug target for ovarian cancer due to its unique structure and expression pattern. Its role in the regulation of cell signaling pathways, particularly the TGF-β signaling pathway, makes it an attractive target for inhibitors of TGF-β signaling. Further research is needed to determine the effectiveness of FAM78B as a drug target for ovarian cancer.

Protein Name: Family With Sequence Similarity 78 Member B

The "FAM78B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM78B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets